We identified that the administration of rSj-Cys significantly reduced the mortality of CLP-induced sepsis and its therapeutic effect took effect through inhibiting the pro-inflammatory cytokines and boosting IL-10 and TGF-β1 cytokines, providing a promising strategy for sepsis therapy in clinical practice. This evidence concerns the gene TGFB1 and Sepsis.